Gyre Therapeutics share price logo

Gyre Therapeutics

NASDAQ: GYRE

$6.67

+0.22

(+3.49%)

Live

as on

Gyre Therapeutics Stock Performance

as on September 5, 2026 at 3:08 am IST

  • Day's Low

    $6.44
    $6.67
    downward going graph

    3.45%

    Downside

  • 52 Week's Low

    52 Week's High

    $5.44
    $9.42
    downward going graph

    18.44%

    Downside

    41.23%

    Upside

    downward going graph

Gyre Therapeutics share price movements today

Previous Close
$6.44
Open
$6.44
Volume
140.6K
Market Cap
$686.0M
Day's Low - High
$6.44 - $6.67
52 Week Low - High
$5.44 - $9.42

Gyre Therapeutics Historical Returns

1 Month Return
+ 4.72 %
3 Month Return
+ 4.04 %
1 Year Return
-15.04 %
3 Year Return
0 %
5 Year Return
0 %

Gyre Therapeutics Stock Fundamentals & Key Indicators

Check Gyre Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$686.0M

EPS (TTM)

-0.1989

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

1.66%

PE Ratio (TTM)

-32.38

Industry PE ratio

-6.69

PEG Ratio

0.3599390556691245

EBITDA

-14.0M

Revenue (TTM)

119.4M

Profit Margin

94.30%

Return On Equity TTM

-15.77%

Gyre Therapeutics Stock Valuation

Track how Gyre Therapeutics P/E has moved over time to understand its valuation trends.

Gyre Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-16.85x)

December 31, 2023

Industry (-6.69x)

December 31, 2025

Today (125.40x)

December 31, 2025

Highest (265.01x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: 125.40x

Gyre Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Gyre Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Gyre Therapeutics image
Gyre Therapeutics
SELL$686.0MNA-32.3894.30%NA
Revolution Medicines image
Revolution Medicines
BUY$44.6B614.61%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$141.1B181.73%32.2186.04%NA
Moderna image
Moderna
BUY$60.2B-64.27%-18.66-12.57%NA
Regeneron image
Regeneron
BUY$84.8B24.12%20.1484.86%0.44%

Stock Returns calculator for Gyre Therapeutics Stock including INR - Dollar returns

The Gyre Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Gyre Therapeutics investment value today

Current value as on today

₹94,273

Returns

-₹5,727

(-5.73%)

Returns from Gyre Therapeutics Stock

-₹12,005 (-12.01%)

Dollar Impact

₹6,278 (+6.28%)

Analyst Recommendation on Gyre Therapeutics Stock

Based on 2 analysts

SELL

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'SELL' rating for Gyre Therapeutics. Average target price of $18.67

Gyre Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Gyre Therapeutics.

What analysts predicted

64.27%UPSIDE

Target Price

$18.67

Current Price

$6.67

Analyzed by

2 Analysts

Target

$18.67

Gyre Therapeutics target price $18.67, a slight upside of 64.27% compared to current price of $6.67. According to 2 analysts rating.

Indian Investors' Interest in Gyre Therapeutics Stock

Search interest for Gyre Therapeutics Stock has decreased by -55% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-55% versus previous 30 day period

Gyre Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
27
25
25
27
22
29
30
37
22
29
Gross Profit
26
24
24
26
21
28
28
35
21
26
Operating Income
8
3
4
0
2
-2
6
0
-9
-14
EBITDA
12
6
4
1
5
-1
8
0
-8
-14
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
1
0
0
0
0
Income Before Tax
12
6
3
0
4
-1
7
0
-9
-14
Income Tax Expense
2
1
1
0
0
0
1
1
0
0
Net Income
7
3
1
0
2
0
3
-1
-8
-10
Net Profit Margin
96.40%
96.95%
96.24%
95.78%
95.95%
96.13%
94.67%
95.31%
94.55%
92.41%

Gyre Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Mar 2022
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
0
-
20
7
102
113
105
116
Gross Profit
0
0
0
11
0
97
108
101
111
Operating Income
-21
-33
-57
-57
-83
9
-67
16
11
EBITDA
-21
-33
-55
-56
-87
10
20
17
16
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
1
1
1
2
Income Before Tax
-21
-30
-55
-56
-87
9
-76
23
14
Income Tax Expense
-
-
-
0
-
5
8
5
4
Net Income
-21
-30
-55
-55
-87
2
-92
12
5
Net Profit Margin
-1161.98%
-357800.00%
0.00%
56.26%
-4.52%
95.31%
95.91%
96.33%
95.35%

Gyre Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
9
3
1
0
3
1
5
-2
-8
-22
Operating Cash Flow
2
-5
1
-2
0
2
4
-5
3
-16
Investing Cash Flow
-7
-8
-2
-2
1
-3
-1
1
-3
9
Financing Cash Flow
0
0
0
0
1
22
0
0
0
0
Change in Cash
-3
-13
0
-4
3
21
3
-3
0
5

Gyre Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Mar 2022
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-21
-30
-55
-56
-87
4
-85
17
9
Operating Cash Flow
-19
-28
-43
-55
-83
10
25
-3
1
Investing Cash Flow
-11
-71
27
9
48
-13
-19
-19
0
Financing Cash Flow
35
111
0
60
49
-
2
2
24
Change in Cash
4
11
-15
14
13
-5
8
-21
25

Mutual Funds that own Gyre Therapeutics Stock

Check out the Mutual Funds with significant holdings in Gyre Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
0.90596%
960624
Fidelity Concord Street Trust
0.227898%
241649
Fidelity Salem Street Trust
0.117669%
124769
VANGUARD SCOTTSDALE FUNDS
0.065992%
69974
SCHWAB CAPITAL TRUST
0.04298%
45574
See all

Global Institutional Holdings in Gyre Therapeutics

Funds
Holdings
Vanguard
0.92%
iShares
0.52%
Schwab
0.11%
SPDR
0.03%
WisdomTree
0.02%
See all

Insights on Gyre Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 22.51M → 29.10M (in $), with an average increase of 22.6% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 513.1% return, outperforming this stock by 528.1%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, GYRE stock has moved down by -2.3%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 4 quarters, 3.61M → -10.60M (in $), with an average decrease of 190.3% per quarter

About Gyre Therapeutics

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
OrganisationGyre Therapeutics
Headquarters12730 High Bluff Drive, San Diego, CA, United States, 92130
IndustryBiotechnology
CEODr. Ying Luo Ph.D.
E-voting on sharesClick here to vote

Key Management of Gyre Therapeutics

Name

Title

Mr. Weiguo Ye

Chief Operating Officer

Ms. Ruoyu Chen

Chief Information Officer

Dr. Yue Xiong Ph.D.

Chief Scientific Officer & Director

Mr. Joshua Bergmann J.D.

General Counsel & Corporate Secretary

Seth Goldblum M.B.A.

Senior Vice President of Corporate Development

Mr. Jialiang Wang Ph.D.

Executive VP & GM

Jing Liu Ph.D.

Senior Vice President of Platform Chemistry

Mark Marino

Senior Vice President of Clinical Development

Mr. Thomas W. Eastling M.D.

Chief Financial Officer

Dr. Ying Luo Ph.D.

CEO, President & Director

FAQs

What is Gyre Therapeutics share price today?

Gyre Therapeutics share price today is $6.67 as on . Gyre Therapeutics share today touched a day high of $6.67 and a low of $6.44.

What is the 52 week high and 52 week low for Gyre Therapeutics share?

Gyre Therapeutics share touched a 52 week high of $9.42 on and a 52 week low of $5.44 on . Gyre Therapeutics stock price today i.e. is trending at $6.67,which is 29.19% down from its 52 week high and 22.61% up from its 52 week low.

What is Gyre Therapeutics's market capitalisation today?

Gyre Therapeutics market capitalisation is $0.00T as on .

How to invest in Gyre Therapeutics Stock (GYRE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Gyre Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Gyre Therapeutics Shares that will get you 0.2249 shares as per Gyre Therapeutics share price of $6.67 per share as on September 4, 2026 at 9:38 pm IST.

What is the minimum amount required to buy Gyre Therapeutics Stock (GYRE) from India?

Indian investors can start investing in Gyre Therapeutics (GYRE) shares with as little as ₹94.485 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹944.85 in Gyre Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Gyre Therapeutics share’s latest price of $6.67 as on September 4, 2026 at 9:38 pm IST, you will get 1.4993 shares of Gyre Therapeutics. Learn more about fractional shares .